This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
ACAD Signs License Deal With Saniona for Rights to Neurology Drug
by Zacks Equity Research
Acadia signs a $610 million exclusive global license agreement with Saniona to develop and commercialize SAN711 for neurological disorder indications.
Merck Stock Up as Winrevair Meets Goal in Advanced PAH Study
by Zacks Equity Research
MRK's study of PAH drug Winrevair in a more advanced form of the disease shows overwhelming efficacy.
Roche to Acquire CAR-T Cell Therapy Focused Poseida for $1.5B
by Zacks Equity Research
RHHBY is all set to acquire Poseida Therapeutics, Inc. and ramp up its pipeline with off-the-shelf cell therapies.
BridgeBio Stock Up on FDA Approval of Cardiovascular Drug
by Zacks Equity Research
BBIO gets a significant boost with the FDA approval of acoramidis for the treatment of adults with transthyretin amyloidosis cardiomyopathy. Stock rises.
Pfizer Inc. (PFE) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
AbbVie Stock Rises After Leerink Partners Upgrades Its Rating
by Zacks Equity Research
Leerink Partners upgrades its rating on ABBV stock from Market Perform to Outperform.
Pharma Stock Roundup: EU Nod for PFE's Hympavzi, NVS Ups Sales View
by Kinjel Shah
EU approval for PFE's hemophilia drug Hympavzi. Novartis upgrades its mid-term sales guidance.
Novartis Raises Sales Outlook for Mid-Term, Acquires Kate Therapeutics
by Zacks Equity Research
NVS expects sales to witness a CAGR of 6% during 2023-2028, up from the earlier projection of 5%. The company acquires Kate Therapeutics to strengthen its portflio of gene therapies.
FDA Accepts Bayer's Application for Label Expansion of Nubeqa
by Zacks Equity Research
Bayer's efforts to expand Nubeqa's label in prostate cancer make progress with the FDA's acceptance of the company's sNDA.
Replimune Stock Rallies on BLA Filing for Melanoma Combo Drug
by Zacks Equity Research
REPL stock soars after submitting a BLA to the FDA seeking accelerated approval for its lead candidate, RP1, in combination with Opdivo for advanced melanoma.
PFE vs. NVO: Which Stock Is the Better Value Option?
by Zacks Equity Research
PFE vs. NVO: Which Stock Is the Better Value Option?
5 Best Value Stocks With Discounted PEG to Boost Your Portfolio Return
by Urmimala Biswas
Here are the five PEG-driven value stocks that fit our screening criteria - INGR, PFE, LDOS, LTM and BABA.
The Zacks Analyst Blog Highlights Adobe, Pfizer, Dollar General, Snap and Ryanair
by Zacks Equity Research
Adobe, Pfizer, Dollar General, Snap and Ryanair are included in this Analyst Blog.
Pfizer Secures Approval for Hemophilia Drug Hympavzi in the EU
by Zacks Equity Research
Following approval from the European Commission, PFE's Hympavzi becomes the first hemophilia medicine in the European Union to be administered via a pre-filled, auto-injector pen.
5 Year-to-Date Laggards to Buy Amid Solid Near-Term Upside Potential
by Nalak Das
These five laggards of this year have double-digit upside left for the rest of 2024. These are: ADBE, PFE, DG, SNAP, RYAAY.
SLN Stock Down Despite Cholesterol Drug Lowering Lipoprotein Levels
by Zacks Equity Research
Silence Therapeutics stock falls despite lowering lipoprotein levels in a phase II study of zerlasiran likely due to concerns regarding its competitive profile.
Bayer Acquires Rights for Cardiovascular Drug From CYTK in Japan
by Zacks Equity Research
BAYRY enters into a collaboration and license agreement with Cytokinetics for the exclusive development and commercialization of aficamten in Japan.
ACRS Stock Up on Licensing Deal With Biosion for Two Immunology Drugs
by Zacks Equity Research
Aclaris stock surges on inking an exclusive license agreement with Biosion for global rights to two of the latter's pipeline candidates, BSI-045B and BSI-502.
These 4 Price-to-Sales Stocks Can Supercharge Your Portfolio Growth
by Rajani Lohia
The price-to-sales ratio is a convenient tool to gauge the value of stocks incurring losses or in an early development cycle. Stocks like AGR, SMP, GBX and PFE hold promise.
The Zacks Analyst Blog Highlights Pfizer, Newmont, Uber, Adobe and Qualcomm
by Zacks Equity Research
Pfizer, Newmont, Uber, Adobe and Qualcomm are included in this Analyst Blog.
Top Analyst Reports for Thermo Fisher, NextEra Energy & Lowe's
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Thermo Fisher Scientific Inc. (TMO), NextEra Energy, Inc. (NEE) and Lowe's Companies, Inc. (LOW).
FDA Accepts SNY and REGN's Dupixent Re-Submitted sBLA for Urticaria
by Zacks Equity Research
The FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for chronic spontaneous urticaria on April 18, 2025.
Buy 5 U.S. Bigwigs on the Dip for Sparkling Returns in the Short Term
by Nalak Das
Five stocks currently available at attractive valuations after sizeable corrections in prices are: PFE, NEM, UBER, ADBE, QCOM.
Eyenovia Stock Tumbles on Termination of Phase III Myopia Study
by Zacks Equity Research
EYEN stock craters on the decision to terminate late-stage myopia study of MicroPine following negative feedback from an independent Data Review Committee.
ALNY Reports Sustained 6-Month Efficacy Data From Amyloidosis Study
by Zacks Equity Research
Alnylam shares interim phase I amyloidosis study data on nucresiran, showing rapid TTR reduction sustained for six months after a single dose.